FDA Approves Sutent for Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
Sutent is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases (RTKs). Sutent is indicated for the treatment of patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer.Posted: January 2006
Related articles
- FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma - November 16, 2017
- FDA Approves Sutent for Rare Type of Pancreatic Cancer - May 20, 2011
- Pfizer Submits New Drug Application for Sutent to FDA - August 10, 2005
Sutent (sunitinib malate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
